key: cord-0974162-3fwa79lb
authors: Speeckaert, Reinhart; Lambert, Jo; Puig, Luis; Speeckaert, Marijn; Lapeere, Hilde; De Schepper, Sofie; van Geel, Nanja
title: Comment on “An Evidence-Based Guide to SARS-Cov-2 Vaccination of Patients on Immunotherapies in Dermatology.”
date: 2021-03-17
journal: J Am Acad Dermatol
DOI: 10.1016/j.jaad.2021.03.038
sha: 84bc78d6364e86b93e00af55b698ce5927a9dbf0
doc_id: 974162
cord_uid: 3fwa79lb

nan

We read with great interest the article of Gresham et al. summarizing the influence of  36 immunotherapies used in dermatology on vaccine-induced immunity. 1 We believe it is crucial to 37 discuss rituximab and mycophenolate mofetil more in-depth as both drugs specifically act on B 38

lymphocytes. confirmed for rituximab. This study can therefore not be used as evidence that the vaccine-induced 49 protection will be adequate in patients receiving rituximab for skin disorders, especially if the vaccine 50 is given earlier than 5 months after the last rituximab dose. Substantial data confirm that in patients 51 on rituximab, vaccination should be administered preferably 6 months after the last rituximab dose. 52

The authors reference another study that led to the conclusion "no significant effect of rituximab on 53 humoral response to fellow fever vaccination". However, this study included only 3 patients on 54 rituximab (3/31) and one of them had the lowest antibody titer of all included patients. 3 Therefore, 55

we believe that no conclusion can be made about the humoral response to yellow fever vaccination 56 based on this study. For systemic immunotherapeutics, the evidence seems to point to a slightly 57 different risk profile as mentioned in the conclusion of the paper as data indicate that rituximab and 58 mycophenolate mofetil carry a higher risk for reduced antibody levels compared to methotrexate, 59

Janus kinase inhibitor (Jaki), and systemic corticoids (Figure 1 ). 60

The authors correctly mention that -although diminished-satisfactory immune responses to 61 vaccination are reached in most Jaki-treated patients. Whether temporary withdrawal of 2-3 weeks 62 before vaccination, as stated in the manuscript, could be an effective approach is less clear. Only 1 63 cited paper mentions withdrawal of Jaki and temporary discontinuation did not improve vaccine-64

induced response rates to PPSV-23 (continuous vs withdrawal; 75.0% vs 84.6%, respectively) or 65 influenza (66.3% vs 63.7%, respectively). 4 As most patients were also receiving methotrexate and the 66 subgroup of patients treated only with Jaki was relatively small, there may be effects on T cell 67 responses not captured by these data. Nonetheless, there is little evidence to recommend temporary 68 withdrawal of Jaki prior to Sars-CoV-2 vaccination. 69

An Evidence-Based Guide to SARS-CoV-2 78 Vaccination of Patients on Immunotherapies in Dermatology

Robust memory responses against influenza vaccination in 81 pemphigus patients previously treated with rituximab

Seroconversion 84 in patients with rheumatic diseases treated with immunomodulators or immunosuppressants, 85 who were inadvertently revaccinated against yellow fever

The effect of tofacitinib on pneumococcal and 88 influenza vaccine responses in rheumatoid arthritis